- Open Access
Reassessing the death risk related to probiotics in critically ill patients
© The Author(s). 2016
- Published: 29 November 2016
The original article was published in Critical Care 2016 20:262
The Letter to this article has been published in Critical Care 2017 21:43
- Systematic Review
- Publication Bias
- Risk Ratio
- Hospital Mortality
Manzanares and colleagues, in their very comprehensive systematic review with meta-analysis , conclude that probiotics prove to be a very useful weapon to reduce infections in critically ill patients, although strong recommendation in support of their use cannot be drawn yet. Indeed, they correctly state that publication bias and heterogeneity of the included studies could undermine their conclusions . Another relevant aspect of the paper is the safety profile of probiotics, a well-known matter of debate: no effect was observed upon length-of-stay, diarrhea, and, most of all, mortality .
With regard to this crucial point, Fig. 3 in  describes the overall effect on hospital mortality, with a risk ratio equal to 0.98 (95% confidence interval 0.82–1.18); obviously the result is not significant but the direction of the effect is in favour of probiotics. It is worth underlining that their Fig. 3 reports a wrong datum about the mortality in the trial by Besselink and colleagues , that is 24 out of 152 patients (as correctly reported in Table 2) and not 14 out of 152 in the probiotics arm.
Reassessing the risk ratio with the meta-analytic software ProMeta 3.0, the overall effect becomes 1.02 (95% confidence interval 0.85–1.22), changing the direction of the effect against the use of probiotics, although the result is not significant. The weight of the results stemming from the trial by Besselink and colleagues  is, for example, clearly apparent in another systematic review with meta-analysis published in Critical Care in 2014 .
In spite of their clinical use for a long time, the exact role of probiotics in many therapeutic settings is still not clear, and safety issues in special populations (pregnant women, immunosuppressed, severe underlying diseases) are the main matter of concern . To this purpose, providing the most precise information is fundamental to support clinicians’ decisions.
No funding was needed for this letter.
Availability of data and materials
AEM was personally responsible for both the writing and revision of the article.
The authors report no potential conflicts of interest with any companies/organizations whose products may be discussed in this manuscript.
Consent for publication
Ethics approval and consent to participate
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Manzanares W, Lemieux M, Langlois PL, Wischmeyer PE. Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis. Crit Care. 2016;20:262.View ArticlePubMed CentralGoogle Scholar
- Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG, Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:651–9.View ArticlePubMedGoogle Scholar
- Gou S, Yang Z, Liu T, Wu H, Wang C. Use of probiotics in the treatment of severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2014;18:R57.View ArticlePubMedPubMed CentralGoogle Scholar
- Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;60(S2):S120–34.Google Scholar